Viking Therapeutics Bets $547.8 Million That Obesity Patients Won't Need Weekly Shots Forever
Published on 10/08/2026 at 05:11 | Editorial boerse-global.de
The obesity drug industry has mastered the art of taking weight off. Keeping it off is a different problem entirely — and Viking Therapeutics is wagering nearly half a billion dollars that it can solve it.
At the center of that bet sits VK2735, the company's lead obesity candidate. Viking has now launched the second part of a maintenance study enrolling roughly 195 adults living with obesity, a trial designed to answer a question that matters more to patients than any headline efficacy number: can the kilos stay gone without a needle every week?
From 21 weeks of shots to a menu of options
The trial's design mirrors the real-world journey of anyone on a GLP-1 therapy. Participants first complete a 21-week induction phase of weekly subcutaneous dosing. Then comes the pivot — a switch to more flexible regimens, including daily or weekly oral tablets and extended injection intervals of two weeks or one month.
That transition is where the science gets interesting. In earlier data, subjects shed between 16% and 19% of their body weight during the 21-week run-in, while the placebo arm managed just 0.1%. The more revealing signal came afterward: patients who moved to biweekly dosing held onto about 90% of their lost weight, and those on a monthly injection retained roughly 85%. Switching to placebo, by contrast, preserved only 61%.
Separately, Viking has reported a placebo-adjusted weight loss of 22% at 33 weeks on a 17.5 mg weekly dose of VK2735 — a figure that stands out against a sector where execution is unforgiving.
Should investors sell immediately? Or is it worth buying Viking Therapeutics?
Rivals stumble, and the bar rises
How brittle sentiment in this space has become was on display recently at Boehringer Ingelheim. According to Bloomberg, the German group's candidate survodutide disappointed investors in a Phase 3 trial among patients with obesity and type 2 diabetes, delivering weight loss of up to 13.1%. The episode is a reminder that lofty expectations demand flawless data.
Viking is also running the large-scale VANQUISH-1 and VANQUISH-2 trials, which are evaluating VK2735 over 78 weeks in adults with and without type 2 diabetes. Late-stage studies of the oral formulation are slated to begin before the end of this year.
A capital raise, not a clinical setback
The pressure on the share price in recent weeks has little to do with the pipeline and everything to do with the balance sheet. About a week ago, Viking closed a combined equity offering and convertible bond sale. Since then, the stock has given up 8.6%, with market participants selling on the dilution created by the enlarged share and convertible issues, according to Reuters.
The transaction grossed roughly $575.0 million, with net proceeds estimated at about $547.8 million. Viking placed 9,035,714 shares at $35.00 apiece and issued 2.00% convertible notes maturing in 2032 totaling $258.75 million.
For existing holders, the dilution stings. From a corporate standpoint, though, the move carries weight: late-stage biotech development devours capital, and locking in more than half a billion dollars in a demanding market removes existential time pressure. A company planning studies into 2027 needs liquidity to operate on its own terms.
Analysts trim targets as the clock ticks
Truist nudged its price target down modestly on Wednesday, from $87 to $85, while keeping a buy rating. The analysts noted in their sector view that the margin for error is shrinking noticeably as 2027 approaches, with the market increasingly demanding differentiated profiles and visible revenue rather than early-stage laboratory promise alone.
Viking Therapeutics at a turning point? This analysis reveals what investors need to know now.
Trading reflected that sober reassessment. The stock closed Wednesday's German session at EUR 25.55, a gain of 1.2% on the day. That still leaves a wide gap to the 52-week high of EUR 39.85 — a discount of 36%. A later reading put the shares at EUR 25.65, up 1.6%.
Results from the maintenance study and the VANQUISH programs aren't expected before 2027, a timeline that reshapes the risk profile considerably. Investors face a multi-year stretch in which interim updates must sustain the narrative while concrete regulatory filings remain distant.
Viking is offering scientifically coherent answers to the most pressing questions in obesity care, and the vision of a convenient maintenance therapy carries enormous potential. Until the data land, the stock remains a high-volatility companion — one suited to shareholders with very long patience.
Ad
Viking Therapeutics Stock: New Analysis - 8 October
Fresh Viking Therapeutics information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
